121 related articles for article (PubMed ID: 36096430)
1. Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial.
Tabarsi P; Anjidani N; Shahpari R; Mardani M; Sabzvari A; Yazdani B; Kafi H; Fallah N; Ebrahimi A; Taheri A; Petrovsky N; Barati S
Clin Microbiol Infect; 2023 Feb; 29(2):215-220. PubMed ID: 36096430
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations.
Tabarsi P; Anjidani N; Shahpari R; Mardani M; Sabzvari A; Yazdani B; Roshanzamir K; Bayatani B; Taheri A; Petrovsky N; Li L; Barati S
Clin Microbiol Infect; 2022 Sep; 28(9):1263-1271. PubMed ID: 35436611
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial.
Tabarsi P; Anjidani N; Shahpari R; Roshanzamir K; Fallah N; Andre G; Petrovsky N; Barati S
Immunology; 2022 Nov; 167(3):340-353. PubMed ID: 35758850
[TBL] [Abstract][Full Text] [Related]
4. Ability of SpikoGen®, an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants.
Honda-Okubo Y; Antipov A; Andre G; Barati S; Kafi H; Petrovsky N
Immunology; 2023 Oct; 170(2):193-201. PubMed ID: 37199229
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.
Petrovsky N
Hum Vaccin Immunother; 2024 Dec; 20(1):2363016. PubMed ID: 38839044
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial.
Nafar M; Mostafaloo N; Firouzan A; Poorrezagholi F; Samadian F; Dalili N; Barati S; Anjidani N; Kafi H; Shahpari R; Bayat M; Kianipour S; Samavat S
Clin Ther; 2022 Dec; 44(12):1566-1576. PubMed ID: 36402595
[TBL] [Abstract][Full Text] [Related]
7. Developmental and reproductive safety of Advax-CpG55.2™ adjuvanted COVID-19 and influenza vaccines in mice.
Sakala IG; Honda-Okubo Y; Petrovsky N
Vaccine; 2023 Sep; 41(41):6093-6104. PubMed ID: 37659896
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunogenicity and safety of SpikoGen®, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial.
Tabarsi P; Mamishi S; Anjidani N; Shahpari R; Kafi H; Fallah N; Yazdani B; Ebrahimi A; Roshanzamir K; Ebrahimi H; Oveisi S; Soltani A; Petrovsky N; Barati S
Int Immunopharmacol; 2024 Jan; 127():111436. PubMed ID: 38147778
[TBL] [Abstract][Full Text] [Related]
9. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
Li L; Honda-Okubo Y; Baldwin J; Bowen R; Bielefeldt-Ohmann H; Petrovsky N
Vaccine; 2022 May; 40(23):3182-3192. PubMed ID: 35465982
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
Bravo L; Smolenov I; Han HH; Li P; Hosain R; Rockhold F; Clemens SAC; Roa C; Borja-Tabora C; Quinsaat A; Lopez P; López-Medina E; Brochado L; Hernández EA; Reynales H; Medina T; Velasquez H; Toloza LB; Rodriguez EJ; de Salazar DIM; Rodríguez CA; Sprinz E; Cerbino-Neto J; Luz KG; Schwarzbold AV; Paiva MS; Carlos J; Montellano MEB; de Los Reyes MRA; Yu CY; Alberto ER; Panaligan MM; Salvani-Bautista M; Buntinx E; Hites M; Martinot JB; Bhorat QE; Badat A; Baccarini C; Hu B; Jurgens J; Engelbrecht J; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R
Lancet; 2022 Jan; 399(10323):461-472. PubMed ID: 35065705
[TBL] [Abstract][Full Text] [Related]
12. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
Honda-Okubo Y; Bowen R; Barker M; Bielefeldt-Ohmann H; Petrovsky N
Vaccine; 2023 Nov; 41(48):7116-7128. PubMed ID: 37863669
[TBL] [Abstract][Full Text] [Related]
13. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
Honda-Okubo Y; Li L; André G; Leong KH; Howerth EW; Bebin-Blackwell AG; Ross TM; Petrovsky N
Vaccine; 2023 Jul; 41(32):4710-4718. PubMed ID: 37355452
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
Hager KJ; Pérez Marc G; Gobeil P; Diaz RS; Heizer G; Llapur C; Makarkov AI; Vasconcellos E; Pillet S; Riera F; Saxena P; Geller Wolff P; Bhutada K; Wallace G; Aazami H; Jones CE; Polack FP; Ferrara L; Atkins J; Boulay I; Dhaliwall J; Charland N; Couture MMJ; Jiang-Wright J; Landry N; Lapointe S; Lorin A; Mahmood A; Moulton LH; Pahmer E; Parent J; Séguin A; Tran L; Breuer T; Ceregido MA; Koutsoukos M; Roman F; Namba J; D'Aoust MA; Trepanier S; Kimura Y; Ward BJ;
N Engl J Med; 2022 Jun; 386(22):2084-2096. PubMed ID: 35507508
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
[TBL] [Abstract][Full Text] [Related]
18. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
[TBL] [Abstract][Full Text] [Related]
19. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
[TBL] [Abstract][Full Text] [Related]
20. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
